11 Papers
66 Citations
Shu Xia is an academic researcher from Huazhong University of Science and Technology. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 5, co-authored 6 publications. Previous affiliations of Shu Xia include Medical College of Wisconsin.
Chat about Author
Papers
Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer
Xiaoyi Huang,Tiezheng Yuan,Meihua Liang,Meijun Du,Shu Xia,Rachel L. Dittmar,Dian Wang,William A. See,Brian A. Costello,Fernando Quevedo,Winston Tan,Debashis Nandy,Graham H. Bevan,Sherri Longenbach,Zhifu Sun,Yan Lu,Tao Wang,Stephen N. Thibodeau,Lisa A. Boardman,Manish Kohli,Liang Wang +20 more
TL;DR: Blood-based small RNAs circulating in blood could be used to predict clinical outcomes in late-stage prostate cancer patients and plasma exosomal miRNAs miR-1290 and -375 are promising prognostic biomarkers for CRPC patients are identified.
660
Prostate cancer risk locus at 8q24 as a regulatory hub by physical interactions with multiple genomic loci across the genome
Meijun Du,Tiezheng Yuan,Kala F. Schilter,Rachel L. Dittmar,Alexander C. Mackinnon,Xiaoyi Huang,Michael Tschannen,Elizabeth A. Worthey,Howard J. Jacob,Shu Xia,Jianzhong Gao,Lori S. Tillmans,Yan Lu,Pengyuan Liu,Stephen N. Thibodeau,Liang Wang +15 more
TL;DR: A chromosome conformation capture (3C)-based multi-target sequencing technology is developed and systematically examined three PC risk regions at the 8q24 locus and their potential regulatory targets across human genome in six cell lines, suggesting that the risk locus may function as a regulatory hub by physical interactions with multiple genes important for prostate carcinogenesis.
60
Cell-free DNA copy number variations in plasma from colorectal cancer patients.
Jian Li,Rachel L. Dittmar,Shu Xia,Shu Xia,Huijuan Zhang,Meijun Du,Chiang Ching Huang,Brooke R. Druliner,Lisa A. Boardman,Liang Wang +9 more
TL;DR: Plasma cfDNA‐based tests can capture tumor‐specific genetic changes and may provide a measurable classifier for assessing clinical outcomes in advanced CRC patients and demonstrates the importance of using plasma (rather than serum) to test tumor‐related genomic variations.
52
Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer
Shu Xia,Shu Xia,Manish Kohli,Meijun Du,Rachel L. Dittmar,Adam M. Lee,Debashis Nandy,Tiezheng Yuan,Yongchen Guo,Yuan Wang,Michael Tschannen,Elizabeth A. Worthey,Howard J. Jacob,William A. See,Deepak Kilari,Xuexia Wang,Raymond Hovey,Chiang Ching Huang,Liang Wang +18 more
TL;DR: The results strongly support the feasibility of using non-invasive liquid biopsies as potential tools to study biological mechanisms underlying therapy-specific resistance and to predict disease progression in advanced prostate cancer.
Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
Shu Xia,Shu Xia,Chiang Ching Huang,Min Le,Rachel L. Dittmar,Meijun Du,Tiezheng Yuan,Yongchen Guo,Yuan Wang,Xuexia Wang,Susan Tsai,Saul Suster,Alexander C. Mackinnon,Liang Wang +13 more
TL;DR: These results demonstrated that the PGA score and cfDNA mutational analysis could be useful tool for the early detection of lung cancer.
44